Purpose / DescriptionIn this single-arm trial, 121 non-cirrhotic adults with genotype 4, 5 or 6 infection were assigned to 12 weeks of glecaprevir-pibrentasvir. Most of these patients (68%) were treatment-naive; 32% were treatment-experienced and all had previously received interferon plus ribavirin or peginterferon plus ribavirin. Nearly all (99%) achieved a sustained virologic response at 12 weeks after completing therapy (SVR12); the only individual who did not achieve an SRV12 had genotype 4 infection and discontinued therapy after only 12 days. Findings from ENDURANCE-4 were published in conjunction with ENDURANCE-2 and SURVEYOR-II, Part 4.